OR WAIT null SECS
Expert poll highlights strength of US pharma sector and advances by emerging markets.
A recent survey of pharma industry experts revealed the US pharmaceutical industry continues to lead global peers in innovation and competitiveness; however, the United States trails China, India, and Germany in overall market growth potential. The survey, CPhI Pharma Industry Rankings, which polled 350 top pharma experts on the strength of major pharmaceutical markets and global performance in 2019, was released in November 2019.
According to the report, the US ranked first in innovation in drug delivery; innovation, knowledge, quality, growth potential for biologics drugs, and came in second to Germany in quality of finished drug products. In addition, the US ranked as the third healthiest market for API manufacturing and API manufacturing quality, behind Japan and Germany.
Availability of the survey and accompanying report, released in a Dec. 5, 2019 press announcement, marked the opening of registration for the fourth annual CPhI North America trade show, scheduled for May 5–7, 2020 at the Pennsylvania Convention Center in Philadelphia.
The US is seen as the most competitive market internationally, as assessed on such variables as tax environment, quality of employees and infrastructure, continuing research potential, and access to capital, among other factors, the show organizers reported in a press statement.
“Our new report on the worldwide pharmaceutical supply chain highlights the continuing importance of the US as an innovator and model of excellence in the global market, even as emerging market competitors such as China and India advance,” Anthony Pombal, CPhI North America Show Director, said in the press statement. “The 2019 report also includes a range of informative and stimulating articles from a diverse group of global industry experts, discussing key developments impacting our ever-changing industry.”
The report includes essays on industry trends including the use of predictive framework in manufacturing to anticipate and proactively address potential issues and challenges; the development of efficient bioprocessing methods to enable the routine industrialization of biopharmaceutical R&D and commercialization; and how a focus on patient centricity will bring impact contract development and manufacturing organizations of the supply chain and patient engagement package in just a few years’ time.
The report and registration information are available on the CPhI North America website.
Source: CPhI North America